History

AICAR (acadesine) is an AICA-riboside first studied as an adenosine-regulating agent. Two clinical programs were pursued and both failed: cardioprotection in coronary bypass surgery (PeriCor, licensed to Schering-Plough for phase III) and relapsed/refractory chronic lymphocytic leukemia (Advancell, who ran phase I/II under the proposed trade name "Acadra"). Its fame in fitness circles traces to a single 2008 Cell paper from Narkar, Evans and colleagues, in which four weeks of AICAR raised running endurance about 44% in sedentary mice — the origin of the "exercise in a pill" framing, which has never been reproduced in humans.

AICAR is a small molecule sold online as an “exercise in a pill.” It is not a peptide, not a hormone, and not a SARM — it is an AICA-riboside that activates the metabolic enzyme AMPK. Its entire reputation rests on a 2008 mouse study showing that sedentary animals given AICAR ran substantially farther. In humans, the actual clinical record is for two unrelated medical uses — heart-surgery protection and a blood cancer — both of which stalled. There is no credible human evidence that it improves endurance, body composition, longevity, recovery, or appearance.

What it is

AICAR is 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside; the clinically developed form is acadesine (CAS 2627-69-2). It is a small-molecule adenosine/AMP analog (an AICA-riboside) — not a peptide. Once inside cells it is phosphorylated to ZMP, an analog of AMP. ZMP mimics a “low-energy” state and activates AMP-activated protein kinase (AMPK), the cell’s metabolic master-switch that governs glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis. That is the basis of the “exercise mimetic” idea.

An important honest caveat: many AICAR effects are AMPK-independent. ZMP also perturbs purine and nucleotide synthesis and modulates other targets. A 2021 systematic review (Višnjić et al., Cells) explicitly documents prominent AMPK-independent actions, and — strikingly — a 2007 human muscle study (below) saw glucose uptake without any detectable muscle AMPK activation. So the clean “AMPK activator” story is an oversimplification even for the one acute human effect that has been measured.

The claims

In the biohacking and fitness market, AICAR is promoted as an “exercise in a pill”: increased endurance and aerobic capacity, fat loss, improved metabolic rate and glucose handling, better recovery, and anti-aging or “longevity” benefits — often with a “non-hormonal, train less / gain more” pitch. These claims are extrapolated almost entirely from mouse data. None of them is supported by human results.

What the evidence actually shows

Animal / preclinical (the strongest “exercise mimetic” data):

The foundational paper is Narkar, Evans et al., “AMPK and PPARδ agonists are exercise mimetics,” Cell 2008. In sedentary mice, four weeks of AICAR raised running endurance ~44% and induced oxidative-metabolism genes. This is the origin of the hype — and it is a mouse result, not human proof.
Extensive rodent and cell-culture work on diabetes, fat oxidation, neuropathy and more exists, but it all remains preclinical.

Human evidence (much thinner — and not for endurance or longevity):

Acute muscle glucose uptake — Cuthbertson et al., Diabetes 2007. In healthy young men, AICAR acutely raised muscle 2-deoxyglucose uptake ~2.1-fold — but without any measurable muscle AMPK activation (AMPK activity and phosphorylation were unchanged), which undercuts the simple mechanism. This is a short acute-physiology study, not evidence of training benefit.
Cardioprotection in heart-bypass surgery — RED-CABG trial, JAMA 2012 (Newman et al.). A large randomized trial of 3,080 patients (of 7,500 planned) was stopped early for futility: no reduction in the composite of all-cause death, nonfatal stroke, or need for mechanical support (5.0% placebo vs 5.1% acadesine). An earlier 5-trial, 4,043-patient individual-patient meta-analysis (Mangano, JAMA 1997) had hinted at benefit, but the definitive trial was negative.
Relapsed/refractory CLL — Van Den Neste et al., Cancer Chemother Pharmacol 2013. A small phase I/II study (24 patients) of IV acadesine established a maximum tolerated / optimal biological dose but did not advance toward approval. The mechanistic rationale (Campàs et al., Blood 2003) was that acadesine induces apoptosis in B-CLL cells but not in T lymphocytes.

Bottom line on evidence: the only human data are for two medical indications that both stalled, plus one acute glucose-uptake study. There is no credible human evidence that AICAR improves endurance, body composition, longevity, recovery, or appearance. Human use for those goals is pure extrapolation from mouse data.

Legal and regulatory status

AICAR is not an approved drug anywhere — for any performance, longevity, metabolic, or cosmetic use. It never gained marketing approval, and both clinical programs (cardioprotection and CLL) failed or stalled.
In the consumer market it is sold only as a research chemical (“not for human consumption”). It is not a dietary supplement and not a cosmetic ingredient with any legitimate approval. Such products are unregulated for purity and identity.
Anti-doping (WADA): AICAR is prohibited at all times (in- and out-of-competition) on the WADA Prohibited List under S4 Hormone and Metabolic Modulators → S4.4 (Metabolic Modulators), specifically S4.4.1 (AMPK activators), where it is a named example alongside BAM15 and MOTS-c. The PPARδ agonist GW1516 (GW501516/Cardarine) sits in the adjacent S4.4 subcategory. This holds in the 2026 Prohibited List. AICAR is not a SARM — SARMs are a separate class (S1 Anabolic Agents). (USADA’s athlete-facing page confirms the “prohibited at all times / Hormone and Metabolic Modulators / experimental, not approved for human use” framing but does not itself cite the S4.4.1 code or GW1516; those specifics come from the WADA list.)

Safety

Most human safety data come from short-term IV infusion in monitored hospital settings, not from chronic self-administration — a very different exposure than how biohackers use it.
Reported dose-related adverse effects at higher IV doses include hyperuricemia, transient anemia and/or thrombocytopenia, renal impairment, and infusion-related hypotension. Lower doses were generally well tolerated in trials.
Real unknowns for biohacking use: there are no long-term human safety data; oral bioavailability is poor (clinical use was IV, so oral products are a poor match for the evidence); research-chemical products are unregulated for purity and identity; and chronic or “wrong-tissue” AMPK activation raises theoretical concerns — USADA explicitly flags potential neurodegeneration and impaired cell division. The preclinical and mechanistic literature describes complex, dose-dependent effects on cell survival, so the compound is not benign.
Net: an experimental compound with no approved human indication, banned in sport, unproven for any biohacking goal, and with real (if dose-dependent) toxicities documented in trials.

Bottom line

AICAR (acadesine) is a small-molecule AMPK activator — not a peptide — whose “exercise in a pill” reputation comes almost entirely from a single 2008 mouse study. Its only human track record is in two failed/stalled medical programs (heart-surgery protection, which was negative in a large trial, and CLL, which never advanced) plus one acute glucose-uptake study that, tellingly, showed no muscle AMPK activation. There is no credible human evidence for endurance, fat loss, recovery, longevity, or appearance. It is an unapproved experimental drug sold only as a research chemical, banned in sport at all times, with documented dose-dependent toxicities and no long-term human safety data.

Evidence grade: No credible evidence.